Incidence and risk factors of infusion reactions in patients with breast cancer administered trastuzumab plus pertuzumab-based regimen

Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero J-M, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Eng J Med 372(8):724–734

Article  CAS  Google Scholar 

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J, APHINITY Steering Committee and Investigators (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Eng J Med 377(2):122–131

Article  Google Scholar 

Wing M (2008) Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction. J Immunotoxical 5(1):11–15

Article  CAS  Google Scholar 

Khoury A, Parihar V, O’steen L, Cherabuddi K (2018) Pertuzumab and trastuzumab infusion related cytokine release syndrome in a chemotherapy naive patient with metastatic breast cancer. Breast J 24(3):383–384

Article  PubMed  Google Scholar 

Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV (2009) Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer 17(1):91–98

Article  PubMed  Google Scholar 

Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM (2014) Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. Oncologist 19(3):228–234

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ring A, Simcock R, Mitra S, Bloomfield D, King J, Simpson S, Sadler G, Webb A (2008) Infusion of trastuzumab maintenance doses over 30 minutes. Ann oncol 19(8):1509–1510

Article  CAS  PubMed  Google Scholar 

Herceptin [PackageInsert]. South SanFrancisco, CA: Genentech, Inc.; October 2010. http://www.gene.com/download/pdf/herceptin_prescribing.pdf Accessed April 11, 2022.

European medicines agency: summary of product characteristics for perjeta (pertuzumab) https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Accessed 20 Apr 2022

Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13(6):725–732

Article  CAS  PubMed  Google Scholar 

National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. (CTCAE) Publish date November 27, 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. Accessed April 11, 2022.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplant 48(3):452–458

Article  CAS  PubMed  Google Scholar 

Nakamura Y, Okamoto W, Kato T, Esaki T, Kato K, Komatsu Y, Yuki S, Masuishi T, Nishina T, Ebi H, Sawada K, Taniguchi H, Fuse N, Nomura S, Fukui M, Matsuda S, Sakamoto Y, Uchigata H, Kitajima K, Kuramoto N, Asakawa T, Olsen S, Odegaard JI, Sato A, Fujii S, Ohtsu A, Yoshino T (2021) Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med 27(11):1899–1903

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 94(7):2217–2224

Article  CAS  PubMed  Google Scholar 

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69(24):9330–9336

Article  CAS  PubMed  Google Scholar 

Wang Y-Y, Zhou Na, Liu H-S, Gong X-L, Zhu R, Li X-Y, Sun Z, Zong X-H, Li N-N, Meng C-T, Bai C-M, Li T-S (2020) Circulating activated lymphocyte subsets as potential blood biomarkers of cancer progression. Cancer Med 9(14):5086–5094

Article  CAS  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif